PUBLISHER: DataM Intelligence | PRODUCT CODE: 1382547
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1382547
Dyspareunia is defined by genital pain that can be experienced before, during, or after intercourse. It is debatable whether this condition can be classified as a sexual disorder or pain disorder as identifying a specific etiology can prove challenging. Dyspareumia can have a significant effect on physical and mental health, as well as quality of life. This activity illustrates the evaluation and management of dyspareunia and highlights the role of the interprofessional team in managing patients with this condition.
The etiology of dyspareunia encompasses structural, inflammatory, infectious, neoplastic, traumatic, hormonal, and psychosocial conditions. Anatomic causes include pelvis floor muscle dysfunction, uterine retroversion, hymenal remnants, and pelvic organ prolapse. Lack of lubrication is most common in reproductive years and is attributable to hormonal as well as sexual arousal disorders.
Increasing awareness about the disease is one of the significant key factors that help the market during the forecast period. Pharmacists are uniquely positioned to address the unmet need for dyspareunia awareness and to counsel postmenopausal women on available treatment options for dyspareunia, including specific information regarding intrarosa for those with moderate to severe dyspareunia. Given that there often is a failure to initiate conversations around VVA in the postmenopausal population, pharmacists with an understanding of potential barriers to discussing this sensitive condition may be better equipped to initiate conversations with patients when appropriate.
For instance, in August 2023, Azure Biotech, Inc., a privately held women's health company that is developing novel formulations of lasofoxifene for vulvovaginal atrophy (VVA), launched an educational campaign to support women with this underserved menopausal health condition affecting millions of women.
According to the National Institutes of Health, women spend 30-40% of their lives in menopause, yet the topic of menopause, symptoms, conditions, and treatments is typically not openly discussed among peers, partners, doctors, and even in the media. The objective of Azure's campaign is to open this dialog and educate the public. Azure has created a website, whatsVVA.com providing valuable resources to this underserved community.
Dyspareunia is usually a treatable disease and has some complications. Regardless of the non-malignant nature of the disease, timely management and intervention are crucial to obviate distressing sequelae. If the patients do not seek prompt, appropriate medical care, it can result in loss of sexual interest and problems with relationships. It also results in significant distress and conflicts among the partners. Dyspareunia can lead to negative impacts on a patient's mental and physical health, body image, relationships, and conceiving efforts, as well as decreased libido and arousal.
The global dyspareunia drugs market is segmented based on disease type, drug type, route of administration, distribution channel and region.
The estrogen segment from the drug class segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Estrogen is a steroid hormone associated with the female reproductive organs and is responsible for developing female sexual characteristics. Estrogen or estradiol is the most common form of estrogen hormone for FDA-approved treatment as hormone replacement therapy (HRT) in managing symptoms associated with menopause.
For instance, in February 2022, Duchesnay Inc., a pharmaceutical company specializing in women's health and part of the Duchesnay pharmaceutical group based in Blainville, Quebec, stated that the first treatment launched by its new ownership and management team to help postmenopausal women across Canada who are suffering from vaginal dryness and painful intercourse. Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) now available across Canada, has been approved by Health Canada as a once-daily prescription treatment for this indication.
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the awareness program launches, collaborations and agreements with key players, advanced medical technology, research and development, public awareness campaigns and others that will drive this region to be highest market share during the forecast period.
For instance, in June 2020, Duchesnay USA, a pharmaceutical company that specializes in women's health, is proud to announce the launch of a new video titled Straight Talk: Sex and the Menopausal Woman. Produced in collaboration with FabOverFifty, a leading online platform for women over 50, this video is the latest in a series of videos offered by Duchesnay USA to educate women about moderate to severe vaginal dryness and dyspareunia due to menopause.
Moreover, in May 2020, Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group, stated a definitive agreement to acquire the U.S. commercial rights to Intrarosa (prasterone) from AMAG Pharmaceuticals, Inc. a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. Intrarosa is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
COVID-19 had a substantial impact on the dyspareunia drugs market where the impact of the COVID-19 pandemic on women's sexual life and frequency of intercourse, as well as stress and anxiety levels. The study also found that deteriorating partner relationships and increased stress and anxiety levels were linked to the pandemic. Doctors should provide anamnesis suggest psychotherapy if applicable, and consider telemedicine for facilitating contact with sexologists during this challenging time.
By Route of Administration
The major global players in the market include: Pfizer, Therapeutics MD, Myovant, Novo Nordisk, Duchesnay USA Inc, Maynepharma, Manus Aktteva Biopharma LLP, Lupin Pharma Canada, Verity Pharma, Teva Pharmaceuticals and among others.
The global dyspareunia drugs market report would provide approximately 69 tables, 58 figures and 187 Pages.
LIST NOT EXHAUSTIVE